Tradestie Institutional Equity Comparison Engine
NUVB vs ZYME โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZYME Overall Edge
ZYME Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zymeworks Inc. (ZYME) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus ZYME at 55.0x Forward P/E and 22.6% operating margin (+828.7% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against ZYME sits in CONSOLIDATION (45th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ZYME
NUVB N/M vs ZYME 55.0x Fwd P/E
Growth & Margin Winner
ZYME
Op Margin -61.2% vs 22.6% ยท YoY +242.6% vs +828.7%
Momentum & Technical Winner
ZYME
1Y -46.9% vs +15.7% ยท 52W Pos 2% vs 44%
Options & Structure Winner
ZYME
BREAKDOWN (26th %ile IV) vs CONSOLIDATION (45th %ile IV)
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
ZYME
NASDAQ
Zymeworks Inc.
Pharmaceutical Preparations
$26.14
-2.68% 1D
Market Cap
$1.9B
1M Return
-8.09%
1Y Return
+15.66%
Forward P/E
55.0x
Unified AI Score
59.5 / 100
HOLD
Tech 60.0
Fund 59.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NUVB -46.85%
ZYME +15.66%
Spread: +62.51 pp (ZYME Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | ZYME Revenue | NUVB Op. Margin | ZYME Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | N/A | $40M | N/A | -481.3% | ZYME |
| FY2021 | N/A | $30M | N/A | -808.2% | ZYME |
| FY2022 | N/A | $410M | N/A | 31.6% | ZYME |
| FY2023 | N/A | $80M | N/A | -181.6% | ZYME |
| FY2024 | $10M | $80M | -7527.3% | -179.7% | ZYME |
| FY2025 | $60M | $110M | -338.7% | -87.3% | ZYME |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NUVB | ZYME | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $1.9B | Larger Scale | ZYME |
| Trailing P/E Ratio Valuation | N/M | 50.7x | Lower Multiple | ZYME |
| Forward P/E Ratio Valuation | N/M | 55.0x | Lower Multiple | ZYME |
| Revenue Growth (YoY) Growth | +242.6% | +828.7% | Higher Growth | ZYME |
| Operating Margin (TTM) Profitability | -61.2% | 22.6% | Higher Margin | ZYME |
| Net Profit Margin Profitability | -67.4% | 16.3% | Higher Margin | ZYME |
| Return on Equity (ROE) Capital Efficiency | -49.1% | 15.0% | Higher ROE | ZYME |
| 52-Week Range Position Momentum | 2% ($4โ$10) | 44% ($22โ$32) | Stronger Trend | ZYME |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 55% Vol | 0.87ฮฒ ยท 56% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 61.0 / 100 (BUY) | 59.5 / 100 (HOLD) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NUVB vs ZYME Buy Guide
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
ZYME
CONSOLIDATION
56d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
45th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NUVB nor ZYME registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.